Source: Pharmaceutical Benefits Scheme (AU) Revision Year: 2021 Publisher: Allergan Australia Pty Ltd, 810 Pacific Highway, Gordon NSW 2072, ABN: 85 000 612 831
Naphazoline constricts the vascular system of the conjunctiva. It is presumed this effect is due to direct action of the drug upon the α-(excitory) receptors of the vascular smooth muscle. It is characterised by a relatively long duration of action and belongs to the imidazoline class of sympathomimetics.
No data available.
No data available.
Genotoxicity was either not assessed or not identified as part of the registration of this medicine.
Carcinogenicity was either not assessed or not identified as part of the registration of this medicine.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
